Regenicin (OTCMKTS:RGIN) and Silk Road Medical (NASDAQ:SILK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
This is a breakdown of recent recommendations for Regenicin and Silk Road Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Silk Road Medical||0||1||3||0||2.75|
Silk Road Medical has a consensus target price of $56.75, indicating a potential downside of 17.41%. Given Silk Road Medical’s higher possible upside, analysts clearly believe Silk Road Medical is more favorable than Regenicin.
Earnings & Valuation
This table compares Regenicin and Silk Road Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Silk Road Medical||$63.35 million||36.53||-$52.42 million||($1.36)||-50.52|
Regenicin has higher earnings, but lower revenue than Silk Road Medical.
Volatility & Risk
Regenicin has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500.
This table compares Regenicin and Silk Road Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Silk Road Medical||-52.69%||-43.15%||-24.88%|
Silk Road Medical beats Regenicin on 5 of the 8 factors compared between the two stocks.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. Its development products include NovaDerm, a cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was founded in 2007 and is based in Little Falls, New Jersey.
About Silk Road Medical
Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.
Receive News & Ratings for Regenicin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenicin and related companies with MarketBeat.com's FREE daily email newsletter.